Premium
Clinical and functional outcomes in patients with major depressive disorder and painful physical symptoms switched to treatment with duloxetine
Author(s) -
Sheehan David V.,
Chokka Pratap R.,
Granger Renee E.,
Walton Richard J.,
Raskin Joel,
Sagman Doron
Publication year - 2011
Publication title -
human psychopharmacology: clinical and experimental
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.461
H-Index - 78
eISSN - 1099-1077
pISSN - 0885-6222
DOI - 10.1002/hup.1199
Subject(s) - duloxetine , anxiety , hamilton anxiety rating scale , mood , population , psychology , hamd , depression (economics) , rating scale , medicine , psychiatry , physical therapy , developmental psychology , alternative medicine , environmental health , pathology , economics , macroeconomics
Objective This post hoc analysis of a multicenter, single‐arm, open‐label trial (the Attributes of Response in Depressed Patients Switched to Treatment with Duloxetine [ARDENT] study) assessed the relationship between functional improvement in the Sheehan Disability Scale (SDS) and clinical outcomes of mood, pain, and anxiety over 8 weeks after switching treatment to duloxetine in patients with major depressive disorder. Methods Analyses included all 195 patients who completed the study. Pearson's correlation and multivariate regression analyses were used to evaluate the relationship between change from baseline in SDS total score and 17‐item Hamilton Rating Scale for Depression (HAMD 17 ) Maier score (mood), Brief Pain Inventory‐Short Form average pain score (pain), and Hamilton Anxiety Rating Scale total score (anxiety) at week 8. Results At week 8, change in SDS total score was positively correlated with change in mood ( r = 0.49), anxiety ( r = 0.44), and pain ( r = 0.40). Multivariate linear regression coefficients for mood and pain were estimated at 1.21 (standard error [SE] = 0.184) and 1.16 (SE = 0.180), respectively (both p < 0.0001) compared with 0.02 (SE = 0.097; p = 0.82) for anxiety. Overall, 43% of patients achieved both HAMD 17 and SDS total remission. Conclusions Functional improvement at 8 weeks was positively correlated with mood, pain, and anxiety in patients with major depressive disorder switched to duloxetine. Change in mood and pain exerted a relatively stronger joint effect on functioning than did anxiety in this patient population. Copyright © 2011 John Wiley & Sons, Ltd.